With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
